

1 **Interplay of antibody and cytokine production reveals CXCL-13 as a potential novel**
2 **biomarker of lethal SARS-CoV-2 infection**

3 Alexander M. Horspool^{1,2}, Theodore Kieffer³, Brynna P. Russ^{1,2}, Megan A. DeJong^{1,2},
4 M. Allison Wolf^{1,2}, Jacqueline M. Karakiozis³, Brice J. Hickey³, Paolo Fagone⁴, Danyel H.
5 Tacker³, Justin R. Bevere^{1,2}, Ivan Martinez⁵, Mariette Barbier^{1,2}, Peter L. Perrotta³, F.
6 Heath Damron^{1,2*}.

7

8

9 ¹ Department of Microbiology, Immunology, and Cell Biology, West Virginia University,
10 Morgantown, West Virginia, USA

11 ² Vaccine Development Center at West Virginia University Health Sciences Center,
12 Morgantown, West Virginia, USA

13 ³ Department of Pathology, Anatomy and Laboratory Medicine, West Virginia University
14 School of Medicine, Morgantown, West Virginia, USA

15 ⁴ Department of Biochemistry, West Virginia University, Morgantown, West Virginia,
16 USA

17 ⁵ West Virginia University Cancer Institute, Morgantown, West Virginia, USA

18 * denotes corresponding author

19 **Abstract:** The SARS-CoV-2 pandemic is continuing to impact the global population. This
20 study was designed to assess the interplay of antibodies with the systemic cytokine
21 response in SARS-CoV-2 patients. We demonstrate that significant anti-SARS-CoV-2
22 antibody production to Receptor Binding Domain (RBD), Nucleocapsid (N), and Spike S1
23 subunit (S1) of SARS-CoV-2 develops over the first 10 to 20 days of infection. The
24 majority of patients produced antibodies against all three antigens (219/255 SARS-CoV-
25 2 positive patient specimens, 86%) suggesting a broad response to viral proteins. Patient
26 mortality, sex, blood type, and age were all associated with differences in antibody
27 production to SARS-CoV-2 antigens which may help explain variation in immunity
28 between these populations. To better understand the systemic immune response, we
29 analyzed the production of 20 cytokines by SARS-CoV-2 patients over the course of
30 infection. Cytokine analysis of SARS-CoV-2 positive patients exhibited increases in
31 proinflammatory markers (IL-6, IL-8, IL-18) and chemotactic markers (IP-10, SDF-1, MIP-
32 1β , MCP-1, and eotaxin) relative to healthy individuals. Patients who succumbed to
33 infection produced decreased IL-2, IL-4, IL-12, IL-13, RANTES, TNF- α , GRO- α , and MIP-
34 1α relative to patients who survived infection. We also observed that the chemokine
35 CXCL13 was particularly elevated in patients that succumbed to infection. CXCL13 is
36 involved in B cell activation, germinal center development, and antibody maturation, and
37 we observed that CXCL13 levels in blood trended with anti-SARS-CoV-2 antibody
38 production. Furthermore, patients that succumbed to infection produced high CXCL13
39 and also tended to have high ratio of nucleocapsid to RBD antibodies. This study
40 provides insights into SARS-CoV-2 immunity implicating the magnitude and specificity of
41 response in relation to patient outcomes.

42 **Introduction:**

43 The SARS-CoV-2 pandemic has drastically affected life in the United States and across
44 the globe. As of August 2020, more than 5.6 million people in the United States have
45 been infected and over 175,000 patients have died¹. SARS-CoV-2 rapidly infected urban
46 centers in California, New York, and other major cities across the United States that until
47 recently were the main source of United States SARS-CoV-2 infections. Studies of anti-
48 SARS-CoV-2 published in the first months of the pandemic were highly focused, with little
49 exploration of the broader immune response in COVID-19 patients. Since then, several
50 factors including elevated pro-inflammatory cytokines and others have been identified in
51 SARS-CoV-2 pathology²⁻⁷ but little is known about the interplay between cytokine
52 production and the antibody response during SARS-CoV-2 infection. CXCL13 is a
53 cytokine integral to germinal center formation⁸⁻¹⁰ and has been used as a biomarker of
54 an anti-infective antibody response⁸. B cells are attracted to the germinal center via
55 production of CXCL13^{11,12} by follicular dendritic cells and T follicular helper cells^{13,14}.
56 Production of CXCL13 and B cell germinal center formation promotes somatic
57 hypermutation and affinity maturation of antibodies with virus-neutralizing function⁸.
58 CXCL13 production is quantifiable in human serum¹⁵, and has not been characterized in
59 the context of coronavirus infection in humans. In this respect, we sought to characterize
60 the interplay of the antibody-mediated immunological response and the cytokine-
61 mediated response to SARS-CoV-2 infection with a focus on CXCL13. We studied well-
62 known markers of anti-viral immunity including: antibody production to the SARS-CoV-2
63 receptor-binding domain (RBD), nucleocapsid (N), and spike s1 (S1) protein domains,
64 Th1 and Th2 associated cytokine production, and CXCL13 production to characterize the

65 immune profile of COVID-19 patients. Our study provides a broad view of the anti-SARS-
66 CoV-2 immune response and reveals that CXCL13 may serve as a novel predictor of
67 lethal infection in COVID-19 patients.

68

69 **Methods:**

70 Patient sampling and analysis: Clinical results of molecular FDA emergency use
71 authorization (EUA) approved assays (Abbott M2000, BD Max, Cepheid GeneXpert) were
72 reviewed by querying an electronic health record (HER, Epic, Verona, WI) at least 3
73 times a week, for admitted in-patients with positive or negative COVID-19/SARS-CoV-2
74 test results at West Virginia University Hospital (WVUH) (see all patient information in
75 Supplementary Data File). All available residual serum and plasma clinical specimens
76 (492 from 82 inpatients, collected from day 0 to day 55 post symptom onset) were then
77 retrieved, de-identified, and stored at -80°C. Electronic medical records were reviewed
78 (IRB #2004976401) for symptoms, date of symptom onset, and patient demographic
79 information (age, sex, mortality). If no symptoms were recorded, the date of admittance
80 was documented as date of symptom onset. Serological results from EUA approved
81 antibody testing (Abbott Architect) performed in the WVUH clinical laboratory and ABO
82 blood type were documented when available. Patient specimens were de-identified by
83 appropriately CITI trained clinical research staff before transfer to the WVU Vaccine
84 Development center research laboratory for testing and aliquoting. Once specimens were
85 thawed for testing, residual specimens were aliquoted into 1 mL cryovials in 0.5 mL
86 increments and frozen at -80°C. No specimens underwent >3 free thaw cycles prior to
87 testing to prevent degradation.

88

89 *Production of SARS-CoV-2 RBD protein:* Production of the SARS-CoV-2 RBD protein
90 was done by transient transfection of the HEK293T cells with a pCAGGS mammalian
91 expression vector containing an RBD construct with a C-terminal hexa-histidine tag and
92 codon optimized for mammalian expression (pCAGGS vector catalog number NR-52309,
93 BEI Resources, Manassas, VA, USA). SARS-CoV-2 RBD protein was produced by
94 transient transfection of HEK293T cells cultured in 300 cm² flasks. Each flask with 60-
95 80% confluent cells was transfected with 60 µg of plasmid DNA complexed with 120 µg
96 of 25 kDa linear polyethylenimine (PEI)(Polysciences Inc., Warrington, PA, USA). The
97 DNA/PEI complex was prepared by slowly adding the PEI solution (0.08 mg/mL in PBS)
98 to the DNA solution (0.04 mg/mL in PBS) with continuous mixing followed by 10 minutes
99 incubation at room temperature; the DNA/PEI complex was then diluted with 45 mL of
100 serum-free DMEM medium and used to replace the FBS supplemented DMEM medium
101 in the flask. For the production of the SARS-CoV-2 N protein, HEK293T cells were
102 harvested 72 hours post transfection and kept at -80C until processing. For the production
103 of the SARS-CoV-2 RBD protein, which is secreted into the culture medium, the cell
104 culture medium was collected after 48 hours, stored at 4°C, and replaced with fresh
105 serum-free DMEM medium; after an additional 48 hour, corresponding to 96 hours post
106 transfection, the medium was collected, pooled with the 48 hour post transfection medium
107 and stored at 4°C until processing. Five hundred mL of medium were supplemented with
108 500 U of Pierce Universal Nuclease (Thermo Fisher Scientific), centrifuged at 4000 x g
109 for 20 minutes and the supernatant filtered through a 0.45 µm PES membrane. The
110 filtered medium was applied onto 5 mL HisTrap FF cartridges (GE Healthcare Bio-

111 Sciences) installed on an AKTA Purifier run with buffer A (20 mM NaH₂PO₄, 0.5 M NaCl,
112 10 mM Imidazole, pH 7.4) and buffer B (20 mM NaH₂PO₄, 0.5 M NaCl, 500 mM Imidazole,
113 pH 7.4). The cartridge was then washed with 20 mM imidazole (98% A, 2% B) and the
114 protein eluted by linear gradient from 2 to 100% buffer B in 10 column volumes. Protein
115 quality was checked by SDS-PAGE and, after dialysis in PBS, the concentration
116 estimated using the Coomassie protein assay and bovine gamma globulin as standard.

117

118

119 SARS-CoV-2 ELISAs: Upon receipt of patient samples, 100µL aliquots were generated
120 and heat-inactivated at 56°C for 1 hour while shaking at 500rpm. Remaining samples
121 were labeled and stored at -20°C or -80°C. When ready to assess antibody concentration,
122 20µL of each sample was added to 100µL of 1% non-fat dry milk diluted in PBS + 0.1%
123 Tween 20 (PBS-T) in the first row of 3 pre-blocked and coated Enzyme-linked
124 Immunosorbent Assay (ELISA) plates (Pierce Part #:15041): one coated with SARS-CoV-
125 2 receptor RBD (2µg/mL), one with N (Sino Biological Part #:40588-V08B) (1µg/mL), and
126 one coated with S1 (Sino Biological Part #: 40591-V08H) (2µg/mL). RBD used to validate
127 the rapid-ELISA prior to serological analysis of patient samples was contributed by David
128 Veesler for distribution through BEI Resources, NIAID, NIH: Vector pcDNA3.1(-)
129 containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Receptor
130 Binding Domain (RBD), NR-52422¹⁶. Samples were diluted five-fold down the plate
131 excluding the final row which served as a negative control for each patient sample. A
132 positive control human monoclonal antibody against an individual antigen was run on
133 each plate to ensure lot-to-lot consistency (human-anti-S1/RBD Sino Biological Part #:

134 A02038 (HC2001), rabbit-anti-N Sino Biological Part #:40143-R001). After sample
135 loading, plates were incubated for 10 minutes at room temperature shaking at 60rpm.
136 Plates were then washed four times with PBS-T. Secondary antibody buffer (100 μ L of 1%
137 milk diluted in PBS-T containing 1:500 goat anti-human-IgG-HRP; Invitrogen Part #:
138 31410) was added immediately following the washing procedure. The plates were
139 incubated for 10 minutes at room temperature shaking at 60rpm. Plates were washed five
140 times with PBS-T. SigmaFast OPD substrate (Sigma Part#: P9187) was prepared in
141 milliQ (18.2M Ω cm) water and 100 μ L was aliquoted into each well. Ten minutes after
142 loading the substrate, 25 μ L of stop solution (3N HCl) was added to end colorimetric
143 development. The absorbance of the substrate in each well was measured on a Synergy
144 H1 (Biotek) spectrophotometer at 492nm. Antibody concentration was calculated based on
145 area under the curve analyses of A_{492} vs. dilution factor plots for each sample.

146
147 Cytokine quantification: Serum cytokine concentrations of IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-
148 8, IL-12, IL-13, IL-18, eotaxin, GM-CSF, GRO- α , IFN- γ , IP-10, MCP-1, MIP-1 α , MIP-1 β ,
149 RANTES, SDF-1 α , and TNF- α were assessed using a Human Th1/Th2 Cytokine &
150 Chemokine 20-Plex ProcartaPlex Panel 1 (ThermoFisher Part #: EPX200-12173-901)
151 according to the manufacturer's instructions. Serum samples (217 samples) were
152 prepared for analysis by heating at 56 $^{\circ}$ C for 1 hour. Samples were then centrifuged at
153 13,000 $\times g$ for 2 mins to pellet aggregates. Samples (25 μ L) were diluted 1:2 with universal
154 assay buffer and incubated at room temperature on an orbital shaker at 500 rpm for 1
155 hour. Select samples (based on sample quantity) were diluted 1:4 or 1:5 with the universal
156 assay buffer, which was taken into account during analysis. A standard curve was

157 generated using antigen standards provided by the manufacturer. Samples were
158 resuspended in 120 μ L wash buffer prior to running on a MAGPIX (Luminex) instrument,
159 and 35 μ L was analyzed per samples. Bead counts below 35 were insufficient for analysis
160 and excluded from the analysis.

161
162 CXCL13 quantification: CXCL13 concentration was determined using a Human BLC
163 (CXCL13) ProcartaPlex Simplex Kit (ThermoFisher Part #: EPX01A-12147-901). Plates
164 were coated with magnetic beads according to the manufacturer's protocol. Plasma
165 samples (25 μ L, 217 samples) from patients were loaded onto coated plates and shaken
166 for 1 hour at 500rpm at room temperature. Plates were washed 2 times with wash buffer
167 while attached to the magnet before the addition of detection antibody. Samples were
168 shaken (500rpm) for 30 minutes at room temperature to allow for detection antibody
169 binding. Plates were then washed 2 times with wash buffer while attached to the magnet.
170 After washing, 50 μ L of Streptavidin-PE (SAPE) was added to each well and the plates
171 shaken (500rpm) for 30 minutes at room temperature. Finally, plates were washed 2 times
172 with wash buffer attached to the magnet before the addition of 120 μ L of reading buffer.
173 Sample aliquots (35 μ L) were read by the Luminex MagPix instrument with a 35-bead
174 detection limit.

175
176 Principal component and heatmap analysis: Serological data from patients tested for
177 cytokine production and antibody production were pooled into Microsoft Excel and
178 imported to ClustVis¹⁷. Data were transformed by the $\ln(x)$ transformation provided in the
179 webtool and grouped with a 95% confidence interval. Groups were based on patient

180 SARS-CoV-2 status and outcome (survived vs. deceased). Heatmap clustering was
181 based on complete cytokine profile.

182

183 Statistical analyses: Statistical analyses were calculated in GraphPad Prism (version
184 8.3.0). Comparisons of two conditions were completed using two-tailed Student's *t*-tests
185 or Welch's *t*-tests in cases where standard deviations were different between groups.
186 Statistical significance of multiple variables was assessed using Brown Forsyth and
187 Welch's one-way ANOVA followed by Tukey's multiple comparison test. Pearson
188 correlation coefficients and *p*-values were calculated in GraphPad Prism using the
189 "Correlation" analysis. In all analyses statistical significance was determined to be $p < 0.05$.

190

191 **Results:**

192 In-patient anti-SARS-CoV-2 antibody production: Antibody binding target and the timing
193 of the antibody response are critical factors in mediating immunity. We evaluated anti-
194 SARS-CoV-2 antibody production to 3 antigens (RBD, N, and S1) in 82 in-patients
195 (Supplementary Table 1) by developing a novel rapid-ELISA technique. Our rapid-ELISA
196 technology evaluates IgG antibody production to the SARS-CoV-2 RBD, N, and S1
197 proteins in approximately 1 hour with greater than 99% accuracy (Supplementary Table
198 2). Our survey of SARS-CoV-2 positive patients demonstrated that antibody (IgG)
199 production to RBD, N, and S1 proteins developed over the first 10 to 20 days post-
200 symptom onset (Figure 1a-c). When comparing antibody production to each antigen, we
201 observed significant IgG production to multiple antigens in the majority of patients tested
202 (219/255 SARS-CoV-2 positive in-patients, 86%), (Figure 1d-f, Supplementary Figure 1,

203 Supplementary Data File). To better understand the kinetics of the antibody response, we
204 plotted IgG production of every patient over time to RBD, N, or S1. Patients produced IgG
205 against RBD rapidly after symptom onset with the peak IgG response occurring 10 days
206 after symptom onset (Figure 1g). Anti-S1 IgG production escalated over a slightly larger
207 period (13 days, Figure 1i) and anti-N IgG production was slower than either anti-RBD or
208 anti-S1 antibody production (22 days, Figure 1h). Taken together, these data describe
209 the breadth and timing of the IgG response to SARS-CoV-2 antigens.

210
211 *Antibody production varies depending on patient population:* Antibody responses are
212 typically different depending on patient demographics and have implications for
213 population-wide immunity. To understand the anti-SARS-CoV-2 IgG response in different
214 populations, we analyzed patient groups based on sex, patient mortality, blood type, and
215 age against anti-RBD, anti-N, or anti-S1 antibody production. As IgG production is more
216 consistently detectable after ten days post-symptom onset^{18,19}, we assessed differences
217 in IgG production beyond ten days post symptom onset. Limiting sample analysis to those
218 greater than ten days post symptom onset did not significantly impact the mean antibody
219 production of the patients (Supplementary Figure 1). Patients who did not survive SARS-
220 CoV-2 hospitalization produced significantly more antibodies to SARS-CoV-2 N than
221 patients that survived infection (Figure 2a). Furthermore, patients that did not survive
222 SARS-CoV-2 infection did not produce different quantities of anti-N antibodies than
223 surviving patients during early infection (Supplementary Figure 2). To accurately assess
224 differences in antibody production independently of disease outcome, we quantified anti-
225 SARS-CoV-2 IgG production in patients who survived infection grouped by biological sex,

226 blood type, and age. We determined that, in our cohort, females significantly produced
227 more anti-S1 IgG than males (Figure 2b). We also observed that blood type was
228 significantly associated with anti-SARS-CoV-2 IgG production (Figure 2c). Blood type B+
229 patients produced significantly more IgG to RBD and S1 than A+ or O+ patients (Figure
230 2c) and A+ patients produced the lowest quantities of anti-RBD and anti-S1 IgG. O+
231 patients produced reduced anti-N IgG relative to A+ or B+ patients. Previous studies have
232 identified that age impacts antibody production to SARS-CoV-2^{20,21}. Our study
233 demonstrates that antibody production against RBD or S1 antigens increased with age
234 (Figure 2d). In contrast, antibody production to N increased in patients over 50 years old
235 but did not continue to increase with age after 80 years of age. This is particularly evident
236 when examining Pearson correlations between age and anti-SARS-CoV-2 IgG production
237 for each antigen (Supplementary Figure 3). Overall, these data document a significant
238 impact of patient demographics on anti-SARS-CoV-2 antibody production.

239

240 *Changes in SARS-CoV-2 patient cytokine responses correlate with disease severity:*

241 Antibody production represents the antigen-specific response to pathogens but is only
242 one facet of immunity. We examined the broader immunological response to SARS-CoV-
243 2 infection by quantifying the production of cytokines involved in a representative subset
244 of SARS-CoV-2 or healthy patients. SARS-CoV-2 patients exhibited significant increased
245 pro-inflammatory cytokine production (IL-6, IL-8, IL-18) and increased chemotactic
246 cytokine production (IP-10, SDF-1, MIP-1 β , MCP-1 and eotaxin) relative to non-infected
247 individuals (Figure 3). Of the SARS-CoV-2-infected patients, mortality was associated
248 with increased IL-6, IL-8, IL-18, IP-10, and MCP-1 production. Patients who succumbed

249 to infection also demonstrated intermediate production of SDF-1, MIP-1 β , and eotaxin
250 production relative to surviving SARS-CoV-2 patients and healthy individuals. We
251 observed no statistically significant differences in several other measured cytokines
252 between healthy and SARS-CoV-2 positive patients. However we observed that lethal
253 SARS-CoV-2 infection was associated with significantly decreased IL-1 β , IL-2, IL-4, IL-
254 12, IL-13, RANTES, TNF α , GRO α , and MIP-1 α , or increased IFN- γ (Supplementary
255 Figure 4). A representation of a surviving patient's cytokine profile (Figure 3i) and
256 deceased patient's profile (Figure 3j) over time are provided. All patient cytokine profiles
257 studied are documented in Supplementary Figure 6. Together, these data demonstrate
258 that SARS-CoV-2 patients exhibit an increased pro-inflammatory and chemotactic
259 response with distinct profiles associated with patient mortality.

260
261 *CXCL13 as a novel predictive tool of lethal SARS-CoV-2 infection:* Infectious disease
262 stimulates germinal center formation promoting high-affinity antibody production^{8,10,22-24}.
263 This response is critical for eradicating many pathogens. As many SARS-CoV-2 patients
264 produced robust antibody responses to multiple antigens, we hypothesized that germinal
265 center formation would be increased in these patients. To quantify this, we measured the
266 serum concentration of CXCL13, a critical mediator of germinal center formation and a
267 biomarker of this immunological response^{8,10,22,23}. We observed that CXCL13 production
268 primarily correlated with peak antibody production to RBD and S1 antigens across SARS-
269 CoV-2 infected patients (Figure 4a-c). Additionally, we observed that there was a
270 significant increase in average production of CXCL13 in positive patients relative to
271 negative SARS-CoV-2 patients. In addition, we discovered that CXCL13 production was

272 significantly increased in patients that did not survive SARS-CoV-2 infection compared to
273 those that did (Figure 4d). When we compared antibody and CXCL13 production based
274 on patient survival over time, we observed that patients who did not survive SARS-CoV-
275 2 infection exhibited a sustained increase in antibody and CXCL13 production relative to
276 surviving patients (Figure 4ef). A full comparison of CXCL13 to anti-SARS-CoV-2 IgGs is
277 provided in Supplementary Figure 5. These results suggest that CXCL13 and intense
278 germinal-center-driven antibody responses are likely associated with lethal SARS-CoV-2
279 infection.

280

281 **Discussion:** Understanding the breadth of the immune response to SARS-CoV-2
282 infection may be critical to better manage SARS-CoV-2 and prevent it from permeating
283 vulnerable communities on a local and global scale. Initially, we used our rapid-ELISA
284 assay to rapidly assess anti-RBD, anti-N, and anti-S1 antibody production in PCR-positive
285 or PCR-negative SARS-CoV-2 in-patients admitted to a WV hospital. Antibody production
286 against multiple SARS-CoV-2 antigens developed over the course of 20 days post-
287 infection in a manner similar to other studies^{19,25–28}. Interestingly, IgG antibody production
288 to N increased over a longer period than antibodies against RBD, or the S1 domain. This
289 could be due to a variety of factors including antigen immunodominance^{29,30}, incongruent
290 antigen processing and availability^{31,32}, differences in antibody utility and turnover, or prior
291 exposure to similar RBD/S1 antigens of other coronaviruses. Theoretically, as N is not
292 expressed on the viral surface, B cells producing antibodies against this antigen may not
293 be selected for as rapidly as those that are specific to the RBD or S1 antigens and may
294 not possess neutralizing function. As infection worsens, more cells lyse. This may

295 increase the local concentration of free nucleocapsid available for antigen processing and
296 presentation, particularly in lymphoid tissue³³. In this respect, a more robust antibody
297 response to nucleocapsid later in infection may be due to increased cellular damage. This
298 may initiate a positive feedback loop where infected cells lyse and release nucleocapsid,
299 which induces a less functional anti-nucleocapsid antibody response that fails to alleviate
300 the cell lysis. More evidence is required to support these hypotheses, but these are
301 interesting paradigms to consider in the context of anti-SARS-CoV-2 immunity.

302 Lethal SARS-CoV-2 infection is significantly correlated with higher antibody
303 production^{19,20,26} and is described further in this study. In analyzing antibody production
304 between patient demographics, it was important to eliminate increased antibody
305 production due to lethal infection as a source of bias. As such, our analyses presented
306 here describe IgG production of SARS-CoV-2 survivors grouped by demographic. There
307 are a multitude of studies reporting differences in IgG production between demographics
308 including: trends in anti-SARS-CoV-2 antibody production between sexes^{20,21,34–36}, a
309 correlation of genetically encoded blood type with SARS-CoV-2 immunity³⁷, and
310 variability in antibody production in the aging population^{20,21}. From these prior studies and
311 others^{38,39} it is known that biological sex can impact antibody production during infection.
312 We observed this phenomenon when quantifying sex specific anti-S1 IgG production. The
313 anti-viral response is mediated in part by Toll-like receptors which are differentially
314 regulated between the sexes^{40,41}. A higher frequency of anti-S1 IgG in females would
315 suggest an increased neutralizing response to the virus which has not been thoroughly
316 evaluated to-date. Our data exhibited a modest difference in antibody production between

317 sexes. As a result, we do not consider biological sex to be a major contributor to anti-
318 SARS-CoV-2 antibody production.

319 It is documented that red blood cell phenotypes can influence microbial
320 pathogenesis as antigens can function as receptors and/or co-receptors for pathogenic
321 organisms⁴². Historically, an association was identified between ABO type and pathogen
322 infectivity during the SARS-CoV Hong Kong hospital outbreak in 2003; during that
323 outbreak a small cohort of type-O healthcare workers showed significantly decreased
324 odds of infection relative to health care workers with other blood types^{42,43}. An additional
325 study demonstrated that antibodies against the A blood type antigen can inhibit SARS-
326 CoV spike protein binding to ACE2⁴⁴. Although the underlying mechanism relating blood
327 type to SARS-CoV-2 pathogenesis remains unclear, it appears there may be a
328 relationship between ABO blood type and coronavirus infection. Recent data identified
329 the 9q34.2 locus (ABO blood group locus) as potentially involved in susceptibility to
330 COVID-19 respiratory failure with evidence that type A phenotypes are at higher risk while
331 type O phenotypes are partially protected⁴⁵. The data generated in these studies show an
332 interesting pattern that may reinforce blood type related outcomes in severe disease due
333 to a previously unreported association to the level and type of antibody response. As seen
334 in Figure 2c, the relative quantity of anti-RBD and anti-S1 antibodies was highest among
335 type-O and -B individuals and lowest in type-A individuals while the opposite is true of
336 anti-N antibodies. This is further accentuated by evaluating the ratio of anti-RBD or anti-
337 S1 versus anti-N in our patient cohort which shows that higher N:RBD or N:S1 ratios are
338 associated with poor prognosis (Supplementary Figure 5). It is plausible that type-A
339 individuals may have a misdirected humoral response due to antigenic homology

340 between N-acetyl-galactosamine sugar moieties on the A antigen and Spike protein
341 resulting in molecular mimicry. This would result in type-O and -B individuals registering
342 more Spike protein epitopes as foreign and eliciting a more robust humoral response; in
343 turn, this putative mechanism could reduce infectious dose and decrease the risk of
344 mortality. Further studies evaluating physiologic modifications of Spike protein and its
345 antigenic moieties would help support or disprove this theory. As the conclusions from
346 these observations are currently theoretical, a more extensive review of comorbid
347 conditions – with a multivariate analysis and estimations of associated odds ratios – may
348 reveal other associations outside of blood type.

349 The aging process is associated with decreased T-cell functionality⁴⁶, resulting in
350 hyperactive B-cell proliferation that does not confer immunity⁴⁷. We discovered that older
351 patients typically produced more antibodies to RBD and S1 than younger patients. The
352 lack of increase in antibody production to nucleocapsid in the elderly may be a function
353 of antigen availability. To speculate, if elderly patients have higher viral loads due to
354 decreased remediation of virus this would increase the relative abundance of surface
355 exposed antigens (RBD and S1), but not necessarily hidden antigens (N). Increased
356 antibody production would therefore predominantly occur to RBD and S1, and not N.
357 Other challenges are associated with studying this population including co-presentations
358 of multiple diseases which complicates this analysis. Regardless, our study has identified
359 several patient demographics associated with differences in the anti-SARS-CoV-2
360 antibody response.

361 The anti-viral immune response depends on a variety of signaling pathways
362 mediated by cytokines and chemokines. Many of the pro-inflammatory cytokines

363 associated with the anti-viral response are upregulated in patients with lethal SARS-CoV-
364 2 infection in our study. IL-6, IL-8, and IL-18 are known pro-inflammatory cytokines that
365 aid in the antiviral response and have been identified in other studies of SARS-CoV-2
366 patients^{2,48-52}. These cytokines are considered part of the “cytokine storm” notorious for
367 inducing localized tissue damage, which may explain the relative increase of these
368 cytokines in deceased patients. In general, the production of these cytokines was similar
369 in SARS-CoV-2 patients to individuals with other lethal viral infections⁵³⁻⁵⁵.

370 Chemotaxis is another critical component of antiviral immunity and several
371 chemotactic mediators were increased in patients from our study. IP-10 is a chemotactic
372 agent that was increased ten-fold in SARS-CoV-2 patients and even more so in deceased
373 SARS-CoV-2 patients. IP-10 is protective in SARS infection^{56,57} suggesting that this may
374 be a critical component of anti-SARS-CoV-2 immunity. In a broader sense, this
375 chemotactic response likely functions by inducing chemotaxis of phagocytic immune cells
376 and activated T cells similar to infection with other viral infections⁵⁸. Several other
377 chemoattractive mediators with similar function were upregulated in SARS-CoV-2
378 patients revealing a systemic increase in leukocyte recruitment (Figure 3, Supplementary
379 Figure 4). Two functional outliers in this analysis were SDF-1 and eotaxin, which are
380 particularly interesting chemokines with broader functional capabilities. SDF-1 is a potent
381 chemoattractant for leukocytes⁵⁹, but has also been implicated in cardiac stress signaling
382 and repair mechanisms⁶⁰⁻⁶². Given increasing reports of cardiac disease concurrent with,
383 or following SARS-CoV-2 infection^{63,64}, the increase in SDF-1 may be an indirect indicator
384 of cardiac distress. Separately, we discovered increased eotaxin production in SARS-
385 CoV-2 patients. Eotaxin was increased or similar to healthy patients during SARS-CoV-2

386 infection in other studies^{49,65}. Eotaxin is typically involved in eosinophil recruitment, which
387 can result in pulmonary damage⁶⁶. This chemokine is upregulated during viral infection⁶⁷,
388 and can inhibit certain viral infections, such as HIV⁶⁸. As patients who survived infection
389 produced significantly more eotaxin than patients with lethal infection, it is possible that
390 eotaxin provides a double-edged function in SARS-CoV-2 immunity.

391 Surprisingly, we did not observe changes in production of a number of other
392 cytokines that are involved in the general anti-viral response (i.e. TNF- α ; Supplementary
393 Figures 4 and 6). Although this was the case, the noticeable decreases in IL-1 β , IL-2, IL-
394 4, IL-12, IL-13, RANTES, TNF α , GRO α , and MIP-1 α observed in patients with lethal
395 SARS-CoV-2 infection, suggest that lethal infection results in an exhausted immune
396 response^{69,70}. When considering the overall cytokine response to SARS-CoV-2 in
397 conjunction with the anti-SARS-CoV-2 antibody response, it is clear that distinct
398 phenotypic clusters of healthy patients, surviving patients, and patients with lethally-
399 infected (Figure 5). In this respect, these analyses paint a more definitive picture of the
400 anti-SARS-CoV-2 cytokine response. Despite the significant results of this study, these
401 data should be evaluated in broader context as patient demographics, treatment plan,
402 and course of infection likely play a role in differences in cytokine production between
403 patients and studies. Large-scale analyses of cytokine production on a population-wide
404 scale would likely be necessary to fully understand the cytokine profile of anti-SARS-CoV-
405 2 immunity.

406 Antibody maturation signaling has not been investigated in the context of SARS-
407 CoV-2. We assessed the activity of the antibody maturation pathway by measuring
408 CXCL13 concentrations in the serum of SARS-CoV-2 patients. Increased CXCL13 in

409 SARS-CoV-2 patients may indicate heightened germinal center activity⁸ and affinity
410 maturation of anti-SARS-CoV-2 antibodies. The significant increase of CXCL13 in
411 patients with lethal disease suggests this may be an emergency response to uncontrolled
412 infection. It is possible that sustained infection stimulates increased antibody affinity
413 maturation that is unable to keep pace with viral replication and the cytokine storm. In this
414 sense, CXCL13 could be used as a marker of SARS-CoV-2 disease severity. There is a
415 precedent for the utility of CXCL13 as a biomarker that is predictive of immune activation
416 during HIV exposure^{8,9,24}. This adds credibility and feasibility for this utility, but further
417 studies are required to validate this approach. We have provided a schematic of how the
418 CXCL13 response interplays with our other observations of SARS-CoV-2 immunity in
419 Figure 6.

420 To summarize, this study provides insight into the breadth of the immunological
421 response against SARS-CoV-2. We demonstrated increasing antibody production to
422 multiple SARS-CoV-2 antigens over the first ten days of infection using a rapid-ELISA
423 assay. Our results exhibit that patient mortality, sex, blood type, and age impact antibody
424 production to SARS-CoV-2, adding to what is known about SARS-CoV-2 pathogenesis.
425 Furthermore, lethal SARS-CoV-2 infection triggers a pro-inflammatory cytokine response,
426 in combination with the secretion of several chemotactic agents. Interestingly, patients
427 with lethal SARS-CoV-2 disease exhibited divergent cytokine production compared to
428 patients with non-lethal disease. Finally, we discovered that a marker of germinal center
429 activity (CXCL13) is upregulated in SARS-CoV-2 patients, and that this upregulation is
430 amplified in lethal disease. Ultimately, these studies help to elucidate the interplay

431 between immunological responses to SARS-CoV-2 and identify a potential novel
432 biomarker of COVID-19 severity.

433

434 **Funding:** This project was supported by the Vaccine Development Center at the West
435 Virginia University Health Sciences Center. FHD and the VDC are supported by the
436 Research Challenge Grant no. HEPC.dsr.18.6 from the Division of Science and
437 Research, WV Higher Education Policy Commission. Funding for generating antigens
438 was provided by the WVU Health Science Center Office of Research and Graduate
439 Education.

440

441 **Acknowledgements:**

442 AMH, TK, and FHD designed the experiments. TK, JMK and BJH compiled and
443 transferred patient data. AMH and BRR ran rapid-ELISA assays of patient samples. AMH,
444 MAW, and MAD performed CXCL13 quantification assays. MAW, and MAD performed
445 20-plex cytokine assays. PF produced RBD used in this study. AMH analyzed and
446 compiled assay data and figures. All authors took part in writing and editing the
447 manuscript. We would like to thank BEI Resources for providing the following reagents
448 (NR-52422). We would finally like to express our gratitude to Drs. Laura Gibson and Clay
449 Marsh for enabling this research during the global pandemic.

450 **References:**

- 451 1. CDC - Coronavirus Disease 2019 (COVID-19) - Cases in the U.S.
- 452 2. Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C. &
453 Melguizo-Rodríguez, L. SARS-CoV-2 infection: The role of cytokines in COVID-19
454 disease. *Cytokine Growth Factor Rev.* (2020) doi:10.1016/j.cytogfr.2020.06.001.
- 455 3. Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-
456 CoV-2 infections. *Nat. Med.* (2020) doi:10.1038/s41591-020-0965-6.
- 457 4. Yang, Y. *et al.* Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-
458 CoV-2 infection is associated with disease severity and fatal outcome. *medRxiv*
459 **2019**, 2020.03.02.20029975 (2020).
- 460 5. Mehta, P. *et al.* COVID-19: consider cytokine storm syndromes and
461 immunosuppression. *Lancet (London, England)* vol. 395 1033–1034 (2020).
- 462 6. Wenjun, W. & Li, H. The definition and risks of Cytokine Release Syndrome-Like
463 in 11 and Retrospective Analysis yimin , Cheng linling , Chen sibe , Nong lingbo
464 , Lin yongping , He COVID-19 , Cytokine Release Syndrome-Like , IL-6 , COVID-
465 19-infected pneumonia patients with s. *medRxiv* (2020).
- 466 7. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019
467 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**,
468 507–513 (2020).
- 469 8. Havenar-Daughton, C. *et al.* CXCL13 is a plasma biomarker of germinal center
470 activity. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 2702–2707 (2016).
- 471 9. Mehraj, V. *et al.* CXCL13 as a biomarker of immune activation during early and
472 chronic HIV infection. *Front. Immunol.* **10**, (2019).

- 473 10. Phares, T. W., Disano, K. D., Stohlman, S. A., Segal, B. M. & Bergmann, C. C.
474 CXCL13 promotes isotype-switched B cell accumulation to the central nervous
475 system during viral encephalomyelitis. **54**, 128–139 (2016).
- 476 11. Legler, D. F. *et al.* B cell-attracting chemokine 1, a human CXC chemokine
477 expressed in lymphoid tissues, selectively attracts B lymphocytes via
478 BLR1/CXCR5. *J. Exp. Med.* **187**, 655–660 (1998).
- 479 12. Armas-González, E. *et al.* Role of CXCL13 and CCL20 in the recruitment of B
480 cells to inflammatory foci in chronic arthritis. *Arthritis Res. Ther.* **20**, 1–12 (2018).
- 481 13. Wang, X. *et al.* Follicular dendritic cells help establish follicle identity and promote
482 B cell retention in germinal centers. *J. Exp. Med.* **208**, 2497–2510 (2011).
- 483 14. Kroenke, M. A. *et al.* Bcl6 and Maf Cooperate To Instruct Human Follicular Helper
484 CD4 T Cell Differentiation. *J. Immunol.* **188**, 3734–3744 (2012).
- 485 15. Widney, D. P. *et al.* Serum Levels of the Homeostatic B Cell Chemokine,
486 CXCL13, Are Elevated During HIV Infection. *J. Interf. Cytokine Res.* **25**, 702–706
487 (2005).
- 488 16. Alexandra C. Walls, Young-Jun Park, M. Alejandra Tortorici, Abigail Wall, Andrew
489 T. McGuire, D. V. Structure , Function , and Antigenicity of the SARS-. *Cell*
490 (2020).
- 491 17. Metsalu, T. & Vilo, J. ClustVis: A web tool for visualizing clustering of multivariate
492 data using Principal Component Analysis and heatmap. *Nucleic Acids Res.* **43**,
493 W566–W570 (2015).
- 494 18. Liu, W. *et al.* Evaluation of nucleocapsid and spike protein-based enzyme-linked
495 immunosorbent assays for detecting antibodies against SARS-CoV-2. *J. Clin.*

- 496 *Microbiol.* **58**, 1–7 (2020).
- 497 19. Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19.
498 *Nat. Med.* **26**, 845–848 (2020).
- 499 20. Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in
500 convalescent individuals. *Nature* (2020) doi:10.1038/s41586-020-2456-9.
- 501 21. Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L.
502 Considering how biological sex impacts immune responses and COVID-19
503 outcomes. *Nat. Rev. Immunol.* **20**, 442–447 (2020).
- 504 22. Stebbeg, M. *et al.* Regulation of the germinal center response. *Front. Immunol.* **9**,
505 1–13 (2018).
- 506 23. Denton, A. E. *et al.* Type I interferon induces CXCL13 to support ectopic germinal
507 center formation. *J. Exp. Med.* **216**, 621–637 (2019).
- 508 24. Epeldegui, M. *et al.* Predictive Value of Cytokines and Immune Activation
509 Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab
510 plus Infusional EPOCH (AMC-034 trial). *Clin. Cancer Res.* **22**, 328–336 (2016).
- 511 25. Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel
512 coronavirus disease 2019. *Clin. Infect. Dis.* 1–22 (2020) doi:10.1093/cid/ciaa344.
- 513 26. Qu, J. *et al.* Profile of IgG and IgM antibodies against severe acute respiratory
514 syndrome coronavirus 2 (SARS-CoV-2). *Clin. Infect. Dis.* 10–13 (2020)
515 doi:10.1093/cid/ciaa489.
- 516 27. Okba, N. M. A. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2-Specific
517 Antibody Responses in Coronavirus Disease Patients. *Emerg. Infect. Dis.* **26**,
518 1478–1488 (2020).


- 519 28. Lee, Y.-L. *et al.* Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among
520 COVID-19 patients. *J. Infect.* S0163-4453(20)30230–9 (2020)
521 doi:10.1016/j.jinf.2020.04.019.
- 522 29. Kusters, J. G. *et al.* ANALYSIS OF AN IMMUNODOMINANT REGION OF
523 INFECTIOUS BRONCHITIS VIRUS ' infectious bronchitis virus . This region near
524 the of four mAb and two by antigenic S2 is explained by features Recognition o.
525 *October* **143**, 2692–2698 (1989).
- 526 30. Mukherjee, S., Tworowski, D., Detroja, R., Mukherjee, S. B. & Frenkel-
527 Morgenstern, M. Immunoinformatics and structural analysis for identification of
528 immunodominant epitopes in SARS-CoV-2 as potential vaccine targets. *Vaccines*
529 **8**, 1–17 (2020).
- 530 31. Kumar, S., Nyodu, R., Maurya, V. K. & Saxena, S. K. Host Immune Response
531 and Immunobiology of Human SARS-CoV-2 Infection. **2019**, 43–53 (2020).
- 532 32. Kiyotani, K., Toyoshima, Y., Nemoto, K. & Nakamura, Y. Bioinformatic prediction
533 of potential T cell epitopes for SARS-Cov-2. *J. Hum. Genet.* **65**, 569–575 (2020).
- 534 33. chen, yongwen *et al.* The Novel Severe Acute Respiratory Syndrome
535 Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph
536 Nodes. **2**, 1–18 (2020).
- 537 34. Zeng, F. *et al.* A comparison study of SARS-CoV-2 IgG antibody between male
538 and female COVID-19 patients: a possible reason underlying different outcome
539 between gender. *medRxiv* 2020.03.26.20040709 (2020)
540 doi:10.1101/2020.03.26.20040709.
- 541 35. Takahashi, T. *et al.* Sex differences in immune responses to SARS-CoV-2 that

- 542 underlie disease outcomes. *medRxiv* 2020.06.06.20123414 (2020)
- 543 doi:10.1101/2020.06.06.20123414.
- 544 36. Chakravarty, D. *et al.* Sex differences in SARS-CoV-2 infection rates and the
- 545 potential link to prostate cancer. *Commun. Biol.* **3**, 1–12 (2020).
- 546 37. Zhao, J. *et al.* Relationship between the ABO Blood Group and the COVID-19
- 547 Susceptibility. *medRxiv* 2020.03.11.20031096 (2020)
- 548 doi:10.1101/2020.03.11.20031096.
- 549 38. Schurz, H. *et al.* The X chromosome and sex-specific effects in infectious disease
- 550 susceptibility. *Hum. Genomics* **13**, 2 (2019).
- 551 39. Gigantesco, A. & Giuliani, and M. Quality of life in mental health services with a
- 552 focus on psychiatric rehabilitation practice. *Ann Ist Super Sanità* **47**, 363–372
- 553 (2011).
- 554 40. Souyris, M. *et al.* TLR7 escapes X chromosome inactivation in immune cells. *Sci.*
- 555 *Immunol.* **3**, 1–11 (2018).
- 556 41. Souyris, M., Mejía, J. E., Chaumeil, J. & Guéry, J.-C. Female predisposition to
- 557 TLR7-driven autoimmunity: gene dosage and the escape from X chromosome
- 558 inactivation. *Semin. Immunopathol.* **41**, 153–164 (2019).
- 559 42. Cooling, L. Blood groups in infection and host susceptibility. *Clin. Microbiol. Rev.*
- 560 **28**, 801–870 (2015).
- 561 43. Cheng, Y. *et al.* ABO Blood Group and Susceptibility to Severe Acute Respiratory
- 562 Syndrome. *JAMA - J. Am. Med. Assoc.* **293**, 1447–1451 (2005).
- 563 44. Guillon, P. *et al.* Inhibition of the interaction between the SARS-CoV Spike protein
- 564 and its cellular receptor by anti-histo-blood group antibodies. *Glycobiology* **18**,

- 565 1085–1093 (2008).
- 566 45. Ellinghaus, D. *et al.* Genomewide Association Study of Severe Covid-19 with
567 Respiratory Failure. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2020283.
- 568 46. Nikolich-Žugich, J. Ageing and life-long maintenance of T-cell subsets in the face
569 of latent persistent infections. *Nat. Rev. Immunol.* **8**, 512–522 (2008).
- 570 47. Minato, N., Hattori, M. & Hamazaki, Y. Physiology and pathology of t-cell aging.
571 *Int. Immunol.* **32**, 223–231 (2020).
- 572 48. Song, P., Li, W., Xie, J., Hou, Y. & You, C. Cytokine storm induced by SARS-
573 CoV-2. *Clin. Chim. Acta* **509**, (2020).
- 574 49. Noroozia, R. *et al.* Altered cytokine levels and immune responses in patients with
575 SARS-CoV-2 infection and related conditions. *Cytokine* **133**, (2020).
- 576 50. Coperchini, F., Chiovato, L., Croce, L., Magri, F. & Rotondi, M. The cytokine storm
577 in COVID-19: An overview of the involvement of the chemokine/chemokine-
578 receptor system. *Cytokine Growth Factor Rev.* **53**, (2020).
- 579 51. Tang, Y. *et al.* Cytokine Storm in COVID-19: The Current Evidence and
580 Treatment Strategies. *Front. Immunol.* **11**, 1–13 (2020).
- 581 52. Catanzaro, M. *et al.* Immune response in COVID-19: addressing a
582 pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
583 *Signal Transduct. Target. Ther.* **5**, (2020).
- 584 53. Bian, J. R. *et al.* Clinical aspects and cytokine response in adults with seasonal
585 influenza infection. *Int. J. Clin. Exp. Med.* **7**, 5593–5602 (2014).
- 586 54. Roberts, L. *et al.* Plasma cytokine levels during acute HIV-1 infection predict HIV
587 disease progression. *Aids* **24**, 819–831 (2010).

- 588 55. Zhang, Y. *et al.* Analysis of serum cytokines in patients with severe acute
589 respiratory syndrome. *Infect. Immun.* **72**, 4410–4415 (2004).
- 590 56. Chen, J. & Subbarao, K. The immunobiology of SARS. *Annu. Rev. Immunol.* **25**,
591 443–472 (2007).
- 592 57. Hsieh, Y. H. *et al.* Candidate genes associated with susceptibility for SARS-
593 Coronavirus. *Bull. Math. Biol.* **72**, 122–132 (2010).
- 594 58. Liu, M. *et al.* CXCL10/IP-10 in infectious diseases pathogenesis and potential
595 therapeutic implications. *Cytokine Growth Factor Rev.* **22**, 121–130 (2011).
- 596 59. Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A. & Springer, T. A. A
597 Highly Efficacious Lymphocyte Chemoattractant, Stromal Cell-derived Factor 1
598 (SDF-1). **184**, 1101–1109 (1996).
- 599 60. Wen, J., Zhang, J.-Q., Huang, W. & Wang, Y. SDF-1 α and CXCR4 as therapeutic
600 targets in cardiovascular disease. *Am. J. Cardiovasc. Dis.* **2**, 20–208 (2012).
- 601 61. Saxena, A. *et al.* Stromal cell-derived factor-1 α is cardioprotective after
602 myocardial infarction. *Circulation* **117**, 2224–2231 (2008).
- 603 62. Bromage, D. I., Davidson, S. M. & Yellon, D. M. Stromal derived factor 1 α : A
604 chemokine that delivers a two-pronged defence of the myocardium. *Pharmacol.*
605 *Ther.* **143**, 305–315 (2014).
- 606 63. Wu, L. *et al.* SARS-CoV-2 and cardiovascular complications: From molecular
607 mechanisms to pharmaceutical management. *Biochem. Pharmacol.* **178**, (2020).
- 608 64. Puntmann, V. O. *et al.* Outcomes of Cardiovascular Magnetic Resonance Imaging
609 in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).
610 *JAMA Cardiol.* **2019**, 1–9 (2020).

- 611 65. Huang*, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus
612 in Wuhan, China. *Lancet* **395**, 497–506 (2020).
- 613 66. Huaux, F. *et al.* Role of eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3)
614 in bleomycin-induced lung injury and fibrosis. *Am. J. Pathol.* **167**, 1485–1496
615 (2005).
- 616 67. Kawaguchi, M. *et al.* Influenza virus a stimulates expression of eotaxin by nasal
617 epithelial cells. *Clin. Exp. Allergy* **31**, 873–880 (2001).
- 618 68. Choe, H. *et al.* The β -chemokine receptors CCR3 and CCR5 facilitate infection by
619 primary HIV-1 isolates. *Cell* **85**, 1135–1148 (1996).
- 620 69. Wherry, E. J. T cell exhaustion. *Nat. Immunol.* **12**, 492–499 (2011).
- 621 70. Ng, C. T., Snell, L. M., Brooks, D. G. & Oldstone, M. B. A. Networking at the level
622 of host immunity: Immune cell interactions during persistent viral infections. *Cell*
623 *Host Microbe* **13**, 652–664 (2013).
- 624



625

626 **Figure 1 | Anti-SARS-CoV-2 IgG response of SARS-CoV-2 in-patients. Antibody (IgG)**


627 production to patients that tested PCR positive (red) or negative (clear) for SARS-CoV-2

628 to RBD (a), N (b), or S1 (c). Correlation of antibody production to RBD vs. N (d) or S1 (e).

629 Correlation of antibody production to N vs. S1 (f). Antibody production of anti-RBD (g),

630 anti-N (h), or anti-S1 (i) antibodies by SARS-CoV-2 positive patients vs. days post SARS-

631 CoV-2 disease onset.



632

633 **Figure 2 | Patient outcome, sex, blood type, and age impact anti-SARS-CoV-2**

634 **antibody production.** IgG production of patients to RBD, N, and S1 separated based on

635 patients outcome to SARS-CoV-2 infection (a). (S) patients that that survived SARS-CoV-

636 2 infection, (D) did not survive infection, (-) = SARS-CoV_2 negative patients. Anti-SARS-

637 CoV-2 antibody production of surviving patients separated based on sex (b), blood type


638 (c), and age (d). Statistical analysis was completed by one-way ANOVA followed by

639 Sidak's multiple comparisons test. Significance was assessed between SARS-CoV-2

640 positive patients and negative patients (#'s) and in between positive patient groups (*'s).

641 ## = $p < 0.01$, ### = $p < 0.001$, #### = $p < 0.0001$, * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$,

642 **** = $p < 0.0001$, n.s. = not significant.



643 **Figure 3 | SARS-CoV-2 patient cytokine profile is impacted by disease severity.**

644 Concentrations of (a) IL-6, (b) IL-8, (c) IL-18, (d) IP-10, (e) SDF-1 α , (f) MIP-1 β , (g)

645 MCP-1, or (h) eotaxin were determined by Luminex technology. Full cytokine profiles for

646 a surviving patient (i) or deceased patient (j). - = SARS-CoV-2 negative patients, + =


647 SARS-CoV-2 positive patients, S = SARS-CoV-2+ patients that survived infection, D =

648 SARS-CoV-2+ patients that did not survive infection. Statistical significance was

649 assessed with a two-tailed Welch's t-test. ** = $p < 0.01$ *** = $p < 0.001$, **** = $p < 0.0001$.

650

651



652

653 **Figure 4 | CXCL13 as novel a biomarker for lethal SARS-CoV-2 infection.** CXCL13

654 concentration was measured in SARS-CoV-2 positive and negative patients. CXCL13


655 production by SARS-CoV-2 production is compared to anti-RBD (a), anti-N (b), or anti-S1

656 (c) IgG quantity over the course of patient disease. Red arrows represent CXCL13

657 maxima, and green arrows represent local IgG maxima. CXCL13 production was

658 compared between SARS-CoV-2 negative (-) and positive (+) patients, and SARS-CoV-
659 2 positive survivors (S), or non-survivors (D) (d). Examples of a surviving patient
660 producing low CXCL13 and low anti-RBD IgG response (e) or deceased patient producing
661 high CXCL13 and high anti-RBD IgG response (f). Statistical significance was assessed
662 with a Brown Forsyth and Welch's one-way ANOVA followed by Tukey's multiple
663 comparison test. **** = $p < 0.0001$, n.s. = not significant.


664



665

666 **Figure 5 | Principal component analysis of anti-SARS-CoV-2 immunological**
667 **responses.** Heatmap (a) and principal (b) component analysis of all patient samples
668 including 20 cytokine concentrations clustered using ClustVis¹⁷.

669



670

671 **Figure 6 | Overview of SARS-CoV-2 immunity.** A schematic of the findings provided in
672 this study (increased immunological markers highlighted in red) in the context of anti-
673 SARS-CoV-2 immunity.